media – Page 20 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

From Booth to Platform—How Digital Tools Are Redefining Global Pharma Engagement

The 36th CPhI Worldwide Exhibition wrapped up in Frankfurt, Germany, on October 30, 2025, bringing together global pharmaceutical professionals for three days of innovation and collaboration. Amid the bustling exhibition halls, a clear shift was visible—business interactions between pharma suppliers and global buyers are moving beyond static displays to tech-enabled, precision matchmaking. Among the exhibitors, Drugdu.com stood out with a forward-thinking presence under the theme “Connect with Real Buyers”. The platform showcased not just its features, but a new approach to international outreach—where the booth becomes a front-line touchpoint, and the platform acts as the digital infrastructure behind global trade. The Drugdu.com team at CPHI Frankfurt 2025 Observation: Booth as a Touchpoint, Platform as a Back-End Engine Unlike traditional static product showcases, more companies are now using their booths as interactive touchpoints for engaging buyers, while relying on digital platforms to support follow-up, qualification, and lead conversion. At CPhI Frankfurt, ...
- Source: drugdu
- 101
- October 31, 2025
【EXPERT Q&A】Why is it necessary to establish a quality management system for medical devices?

Drugdu.com expert’s response: Establishing a quality management system for medical devices is a critical measure to ensure their safety and effectiveness, safeguard patient health, meet regulatory requirements, enhance corporate competitiveness, and promote the healthy development of the industry. The specific reasons are as follows: I. Ensuring the Safety and Effectiveness of Medical Devices Direct Impact on Patient Health: The quality of medical devices directly influences the accuracy of diagnosis, efficacy of treatment, and speed of recovery for patients. For instance, defects in implantable cardiac stents may lead to thrombosis or stent fracture, endangering the patient’s life; inaccuracies in diagnostic reagents can result in misdiagnosis, delaying timely treatment. Reducing Medical Risks: Systematic quality management enables the identification and control of potential risks throughout production, transportation, and usage, minimizing the likelihood of product failures or malfunctions and thereby reducing the incidence of medical accidents. II. Meeting Regulatory and Compliance Requirements International Standards: ...
- Source: drugdu
- 66
- October 31, 2025
Sinovac’s trivalent influenza vaccine has been expanded to cover all age groups, including those 6 months and older.

According to Sinovac BiotechNews: On October 23, 2025, Beijing Sinovac Biotech Co., Ltd. produced a trivalent influenza vaccine.The National Medical Products Administration (NMPA) has approved the expanded age range for the Sinovac Biotech vaccine Anlelaifu® (0.5ml/dose), increasing the target population to include individuals aged 6-35 months and expanding the applicable population to all individuals aged 6 months and older. This month, Sinovac’s quadrivalent influenza vaccine (0.5ml/dose) and trivalent influenza vaccine (0.5ml/dose) have also received approval for expanded age ranges, meaning the company’s seasonal influenza vaccines now offer a unified dosage form for individuals aged 6 months and older. Source: https://finance.eastmoney.com/a/202510303549825713.html
- Source: drugdu
- 89
- October 30, 2025
Jiuzhitang plans to acquire and increase its investment in Jixianglong to enter the field of polypeptide raw materials.

Shanghai Securities News China SecuritiesOn the evening of October 29th, Jiuzhitang…The company announced that it plans to acquire a portion of the equity of Harbin Jixianglong Biotechnology Co., Ltd. for RMB 210 million and increase its capital in Jixianglong by RMB 100 million. After the aforementioned transactions are completed, Jiuzhitang will hold 51.6667% of the equity of Jixianglong, and Jixianglong will be included in its consolidated financial statements. It is understood that Jixianglong is a company specializing in peptide generic drug raw materials, peptide drug formulations, and innovative drugs.Jixianglong is a national high-tech enterprise specializing in R&D, production, and technical services, possessing core technologies and processes for the large-scale production of peptide APIs. Jixianglong currently holds 10 API production licenses, 1 formulation license, and 1 API pending approval; 8 of its products are included in national centralized procurement. It ranks third in China in the number of peptide API licenses, with atosiban and oxytocin being ...
- Source: drugdu
- 71
- October 30, 2025
“Rice-based blood production” attracts capital investment, boosting the market value of Heyuan Bio. What impact will this have on the blood products industry?

In the medical world, human serum albumin is hailed as a “golden life-saving drug.” It is the most widely used blood product, yet it remains trapped in traditional constraints—relying entirely on human plasma extraction. This not only leads to a perennial shortage of clinical supplies but also leaves the risk of viral transmission ever-present. Recently, Heyuan Bio, which just listed on the Science and Technology Innovation Board, is bringing with it “rice hematopoietic” technology, which is expected to break the limitations of traditional methods for preparing human serum albumin. The birth of Heyuan Biotechnology stems from a technological breakthrough by Professor Yang Daichang’s team at Wuhan University. In 2006, Yang Daichang founded Heyuan Biotechnology with his technological achievements. In July of this year, Heyuan Biotechnology’s core product HY1001 (Aofumin Recombinant Human Albumin Injection) was approved for marketing, becoming the first plant-derived recombinant human albumin drug in China. The capital market ...
- Source: drugdu
- 108
- October 30, 2025
US pharmaceutical giants find themselves in a passive position as the government ignores lobbying efforts and continues to ease approval requirements for generic drugs.

The U.S. government announced on Wednesday that it will expedite the approval process for complex biosimilars and relax the requirements for biosimilars developed using live cell technology, no longer requiring human trials as a prerequisite for developing biosimilars. This policy is expected to threaten some of the most profitable products in the U.S. pharmaceutical industry. Pharmaceutical industry leaders had previously lobbied intensely, spending millions of dollars to block the change, but ultimately failed. The U.S. Food and Drug Administration’s (FDA) move to expedite the approval of generic drugs is based on the recent agreement reached between U.S. President Trump and pharmaceutical companies to lower drug prices, which undoubtedly puts greater pressure on the pharmaceutical industry’s profits. So far this year, US pharmaceutical stocks have significantly underperformed the S&P 500 index, with Eli Lilly…PfizerCompanies like Merck have issued pessimistic outlooks due to uncertainty surrounding US policies, warning investors of potential profit risks. ...
- Source: drugdu
- 60
- October 30, 2025
FDA Announces New Biosimilar-Targeted Draft Guidance

FDA is taking aim at expensive biologic drugs. The agency announced new draft guidance to simplify biosimilarity studies and reduce clinical testing that it has deemed “unnecessary.”1 The goal of these moves, according to the agency, is to make it easier for pharmaceutical companies to develop biosimilars. What impact will FDA’s actions have on biosimilar development? FDA says that this will bring more low-cost alternatives to the market at a faster, more reliable rate. The new guidance is titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.” In a press release, Health and Human Services Secretary Robert F. Kennedy Jr. said, “Today’s announcement of biosimilar reform furthers President Trump’s directive to lower drug prices for the American people. Biologics treat many chronic diseases, but for too long, a burdensome approval process has kept patients from accessing more affordable biosimilars. ...
- Source: drugdu
- 65
- October 30, 2025
Injectable Drug Helps Asthma Patients Clear Mucus-Clogged Airways

By Dennis Thompson HealthDay ReporterWEDNESDAY, Oct. 29, 2025 (HealthDay News) — An anti-inflammation injectable drug can reduce mucus buildup and improve breathing among asthma patients, a new clinical trial says. The drug dupilumab (Dupixent) effectively clears up airways plugged by mucus during an asthma attack, researchers reported Oct. 27 in the American Journal of Respiratory and Critical Care Medicine. Results found half as many patients had mucus-plugged airways following treatment with the drug. “In moderate-to-severe asthma, a buildup of mucus in the lungs can obstruct breathing airways to the point where affected patients suffer limited breathing, severe asthma attacks, and even death,” lead researcher Dr. Celeste Porsbjerg said in a news release. She’s a professor of severe asthma at Bispebjerg Hospital in Copenhagen, Denmark. Everyone has some mucus in their system, but it typically isn’t bothersome unless we’re stricken with a cold or the flu, researchers noted. But mucus can ...
- Source: drugdu
- 89
- October 30, 2025
Warsaw Medical Expo

Organiser：Ptak Warsaw Expo Time：November 25 – November 27, 2025 Address：Aleja Katowicka 62, 05-830 Nadarzyn Exhibition hall：PTAK WARSAW EXPO Product range: Medical facilities, equipment, and specialized furniture Specialized equipment and medical devices Medical facility management Medical industry software and IT systems Laboratory diagnostics – devices, equipment, instruments, accessories, reagents Radiological imaging diagnostic equipment Innovative medical solutions and technologies Disposable materials and small-scale equipment Medical staff uniforms and protective clothing Hygiene products and care products, sterilization Disposal services, emergency medical services – equipment and services Rehabilitation – equipment, materials, services Pharmaceuticals – medicines, dietary supplements, medicinal cosmetics Healthcare and services Medical education and training Scientific research Organizations related to the medical industry About Warsaw Medical Expo： The Warsaw Medical Expo in Poland is an event that showcases modern medical technologies, professional equipment, and innovative diagnostic and rehabilitation solutions. It is an excellent opportunity to stay informed about medical trends. This ...
- Source: drugdu
- 149
- October 30, 2025
Eli Lilly deploys the world’s largest AI-powered pharmaceutical factory, anticipating explosive growth.

According to reports, Eli LillyThe company has deployed the world’s largest and most powerful AI pharmaceutical factory, which uses NVIDIA- basedDGX supercluster based on Blackwell architecture. In terms of drug discovery, AI can identify potential drug targets and assist in drug molecule design by analyzing massive biomedical data. Using machine learning algorithms, AI can predict the structure, activity, and toxicity of compounds, quickly screen out candidate drugs with clinical potential, and shorten drug development time. According to TouBao Research Institute, from 2019 to 2023, the scale of China’s AI pharmaceutical market will increase from 70 million yuan to 410 million yuan, with a compound annual growth rate of 57.4%. It is estimated that from 2024 to 2028, the market size will increase from 730 million yuan to 5.86 billion yuan, with a compound annual growth rate of 68.5%. Soochow SecuritiesThe research report points out that the AI pharmaceutical industry is gradually entering a ...
- Source: drugdu
- 116
- October 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.